# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>SECTION</th>
<th>CONTENTS</th>
<th>PAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>II</td>
<td>Vision, Mission &amp; Values</td>
<td>4</td>
</tr>
<tr>
<td>III</td>
<td>ISPAD Officers</td>
<td>5</td>
</tr>
<tr>
<td>IV</td>
<td>ISPAD President’s Report</td>
<td>6-8</td>
</tr>
<tr>
<td>V</td>
<td>ISPAD Secretary General's Report</td>
<td>9-33</td>
</tr>
<tr>
<td>VI</td>
<td>ISPAD Communications Report</td>
<td>34-39</td>
</tr>
<tr>
<td>VII</td>
<td>ISPAD Treasurer’s Report</td>
<td>40-48</td>
</tr>
<tr>
<td>VIII</td>
<td>Society Figures &amp; Numbers</td>
<td>49-54</td>
</tr>
</tbody>
</table>
I. Introduction

The ISPAD Executive Board is honoured to present the Activity Report of the Society for 2020-2022 (July 1, 2020, to December 31, 2022). The Society thrives on its membership, and we are grateful for your views and comments, together with ideas on how to take ISPAD forward in the coming year.

Carine de Beaufort
President 2020-2022

Jamie Wood
Secretary General 2020-2024

Lars Krogvold
Treasurer 2019-2023
I. **Vision, Mission and Values**

Globally, diabetes is a disease in evolution affecting more and more children and adolescents. ISPAD is a professional organization whose aims are to promote clinical and basic science, education and advocacy in childhood and adolescent diabetes. The strength of ISPAD lies in the scientific and clinical expertise of its members regarding all aspects of diabetes in children, adolescents, and young adults. ISPAD is the only international society focusing specifically on all types of childhood diabetes.

**Our Vision**
A better world for children, adolescents, and young adults with diabetes.

**Our Mission**
To bring together professionals from various disciplines with an interest in clinical care, science, education, and advocacy to prevent, treat or cure all forms of diabetes in youth by promoting networking and collaboration. Our aims are:

- To ensure appropriate treatment is available and especially insulin, self-monitoring equipment and all vital supplies required for diabetes care
- To increase awareness of all types of diabetes and prevent delayed diagnosis
- To reduce the morbidity and mortality caused by acute and chronic complications
- To ensure education of youth, families, and other caregivers
- To promote education of diabetes healthcare teams worldwide
- To foster diabetes research
- To prepare and disseminate clinical practice guidelines and standards

**Our Values**

**Excellence**
in care based on rigorous and ethical research with respect for the individual child, adolescent, and family and by creating, evaluating, and disseminating diabetes knowledge.

**Collaboration**
with national and international patient and professional organizations, healthcare providers, policy makers and companies that make products or provide services for youth with diabetes.

**Advocacy**
for children and caregivers to improve awareness that diabetes is different for children than for adults, to end discrimination based on a child’s diabetes, to ensure that proper diabetes care is available in all schools, and to obtain increased funding for diabetes treatment, research, and prevention.
### III. ISPAD Officers

#### Executive Board Members

<table>
<thead>
<tr>
<th>October 2019 - 2020</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim Donaghue, MBBS, PhD, Australia</td>
<td>Jamie Wood, MD, United States</td>
</tr>
<tr>
<td><em>President</em></td>
<td><em>Director of Communications &amp; Secretary General Elect</em></td>
</tr>
<tr>
<td>David Maahs, MD, PhD, United States</td>
<td>Lars Krogvold, MD, PhD, Norway</td>
</tr>
<tr>
<td><em>Secretary General</em></td>
<td><em>Treasurer</em></td>
</tr>
<tr>
<td>Carine de Beaufort, MD, PhD, Luxembourg</td>
<td>Eduardo Calliari, MD, Brazil</td>
</tr>
<tr>
<td><em>President-elect</em></td>
<td><em>Director of Communications in Training</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>October 2020 - 2022</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Carine de Beaufort, MD, PhD, Luxembourg</td>
<td>Luís Eduardo Calliari</td>
</tr>
<tr>
<td><em>President</em></td>
<td><em>Director of Communications</em></td>
</tr>
<tr>
<td>Jamie Wood, MD, United States</td>
<td>Lars Krogvold, MD, PhD, Norway</td>
</tr>
<tr>
<td><em>Secretary General</em></td>
<td><em>Treasurer</em></td>
</tr>
<tr>
<td>Kim Donaghue, MBBS, PhD, Australia</td>
<td>Roque Cardona-Hernández</td>
</tr>
<tr>
<td><em>Past President</em></td>
<td><em>Director of Communications in Training</em></td>
</tr>
</tbody>
</table>

#### Advisory Council Members 2020-2022

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-2020</td>
<td>Anna Lindholm Olinder</td>
<td>Sweden</td>
</tr>
<tr>
<td>2017-2020</td>
<td>Linda Anne DiMEglio</td>
<td>USA</td>
</tr>
<tr>
<td>2017-2020</td>
<td>Asma Deeb</td>
<td>UAE</td>
</tr>
<tr>
<td>2017-2020</td>
<td>Thomas Kapellen</td>
<td>Germany</td>
</tr>
<tr>
<td>2018-2021</td>
<td>Farid Mahmud</td>
<td>Canada</td>
</tr>
<tr>
<td>2018-2021</td>
<td>Ingrid Libman</td>
<td>USA</td>
</tr>
<tr>
<td>2018-2021</td>
<td>Declan Cody</td>
<td>Ireland</td>
</tr>
<tr>
<td>2018-2021</td>
<td>Sarah Ehtisham</td>
<td>UAE</td>
</tr>
<tr>
<td>2018-2021</td>
<td>Katarzyna Gajewska</td>
<td>Ireland</td>
</tr>
<tr>
<td>2019-2022</td>
<td>Roque Cardona-Hernández</td>
<td>Spain</td>
</tr>
<tr>
<td>2019-2022</td>
<td>Julia von Oettingen</td>
<td>Canada</td>
</tr>
<tr>
<td>2019-2022</td>
<td>Helen Phelan</td>
<td>Australia</td>
</tr>
<tr>
<td>2020-2023</td>
<td>Paul Wadwa</td>
<td>USA</td>
</tr>
<tr>
<td>2020-2023</td>
<td>Jenny Couper</td>
<td>Australia</td>
</tr>
<tr>
<td>2020-2023</td>
<td>Klemen Dovc</td>
<td>Slovenia</td>
</tr>
<tr>
<td>2020-2022</td>
<td>Laurel Messer</td>
<td>USA</td>
</tr>
<tr>
<td>2020-2023</td>
<td>Zdenek Sumnik</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>2021-2024</td>
<td>Brynn Marks</td>
<td>USA</td>
</tr>
<tr>
<td>2021-2024</td>
<td>Tiago Jeronimo</td>
<td>Brazil/Spain</td>
</tr>
<tr>
<td>2021-2024</td>
<td>Rade Vukovic</td>
<td>Croatia</td>
</tr>
<tr>
<td>2021-2024</td>
<td>May Ng</td>
<td>UK</td>
</tr>
<tr>
<td>2022-2025</td>
<td>Leena Priyambada</td>
<td>India</td>
</tr>
<tr>
<td>2022-2025</td>
<td>Agata Chobot</td>
<td>Poland</td>
</tr>
<tr>
<td>2022-2025</td>
<td>Sheryl Salis</td>
<td>India</td>
</tr>
<tr>
<td>2022-2025</td>
<td>Cari Berget</td>
<td>USA</td>
</tr>
</tbody>
</table>

#### JENIOUS Group Leadership

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-2020</td>
<td>Klemen Dovc</td>
<td>Slovenia</td>
</tr>
<tr>
<td>2016-2021</td>
<td>Elisa Giani</td>
<td>USA</td>
</tr>
<tr>
<td>2020-2022</td>
<td>Tiago Jeronimo</td>
<td>Brazil/Spain</td>
</tr>
<tr>
<td>2021-2023</td>
<td>Agata Chobot</td>
<td>Poland</td>
</tr>
<tr>
<td>2022-2024</td>
<td>Claudia Piona</td>
<td>USA</td>
</tr>
</tbody>
</table>

#### Corporate Relations Advisor

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sylvia Lion</td>
<td>France</td>
</tr>
</tbody>
</table>

#### ISPAD Historian

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stuart Brink</td>
<td>USA</td>
</tr>
</tbody>
</table>
IV. ISPAD President’s Report

by Carine de Beaufort

The recent years (between 2020 and the start of 2022) have been marked by the Sars-COV2 pandemic and the necessary public health measures that were implemented during that time. The fear of illness and its effects on children, which led to restrictions on their crucial interactions with peers of a similar age, has left its mark. It is now necessary to take a different approach in order to keep making the world a better place for children, adolescents, and young adults with diabetes in any form.

Many of us were unaware of what it would entail to restrict both local and global communication to only a virtual one. The last two years have shown that we can accomplish a lot even when we only meet virtually. I would like to thank the membership and partners of ISPAD for making this possible because it truly demonstrates the dedication of many people around the world to work together to achieve our goals. Partnerships for Advocacy, Science and Education have been created and maintained.

JENIOUS Group (the young professionals who play a crucial role in the Society) and member-initiated surveys have produced pertinent reports that demonstrate flexibility and changes in the provision of clinical care. Additionally, they discovered that the pandemic and the necessary health measures had a significant impact on young people with T1D. (JENIOUS Research Activities are available here: https://www.ispad.org/jenious)

An important milestone is the publication of the Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study (Sept 2022). This study started with a survey among ISPAD members (under the leadership of the past president Kim Donaghue), which formed the basis for the fantastic collaboration with our partners at JDRF, LFAC, IDF and BeyondT1.

The result was a thorough report on the burden of type 1 diabetes and the substantial number of missing persons, suggesting the premature mortality of persons with type 1 diabetes. The now publicly available Type 1 Diabetes Index model, (T1DIndex.org) will hopefully become an important tool to stimulate broader action to support delivery of health care, advocacy, and funding decisions for type 1 diabetes.

These partnerships are incredibly important to move forward, together. Intensified collaboration within Europe in policy development (EUDF – European Diabetes Forum) and WHO (Global Diabetes Compact), to move forward regionally and globally in diabetes for all ages but more specifically in children, adolescents, and young adults. ISPAD has joined the IPA (International Pediatric Association) and we hope to work together on the NCDs.

The ongoing collaboration with LFaC and CDiC is highly valued and with the support of both we hope to contribute to the achievement of WHO targets for 2030.

ISPAD signed a MoU with the PEN-Plus organization to support this organization in their effort to reduce the non-communicable disease (NCD) burden among the poorest children and young adults. PEN-Plus is an integrated care delivery strategy with a focus on several non-communicable conditions for Low and Lower middle-income countries in order to increase access to care for children and young adults in these countries.

Professional partnerships with scientific societies have benefitted from joint symposia and the development of educational programs. An example is the E-learning program with the European Society
for Pediatric Endocrinology (ESPE), and this year several chapters can now be used to obtain CME points, a crucial step forward. E-learning is not limited to the ISPAD@ESPE program, but several webinars have been organized, offering interested persons free access to ‘state of the art’ presentations and discussions.

Although there have been challenges with the e-learning App’s development that have not yet been overcome, I’m optimistic that they will be in the coming years.

- Two new programs have been developed and launched on the continent of Africa: the ISPAD ADECA Education for Health care professionals in Africa – ADECA – (lead Chizo Agwu, an incredible team of ISPAD and Tanzania, and supported by LfaC and ISPAD) and
- PEDAF a French language program for pediatric endocrinology and diabetes with a Basic virtual part (for all interested persons) and a Master program at the universities of Dakar and Yaoundé.

A special thanks to Dr Line Kleinebreil and the team of the UNFM, who have been instrumental in getting the content online and accessible for regions with low bandwidth internet. First reports and links can be found on the ISPAD website. (PEDAF: [https://e-pedaf.org/site](https://e-pedaf.org/site), ADECA: [https://www.ispad.org/page/ADECA2023](https://www.ispad.org/page/ADECA2023)).

I want to express my gratitude once more for the partnerships with numerous and active people in the field that have helped these programs advance.

The president’s message was published in the ISPAD newsletter each month. This has made it possible for people with diabetes from many different regions and age groups to express their opinions and make comments.

This year provided another highlight with the revised ISPAD Clinical Practice Consensus Guidelines 2022. Access to healthcare is not a given everywhere, which stresses the importance to include the contribution of authors from different regions, experience, and the input of persons with diabetes or their caregivers.

It takes a tremendous amount of effort to provide these ’state-of-the-art’ Guidelines on the many relevant domains in Pediatric, Adolescent, and Young Adult diabetes, which are based on evidence and consensus.

This work, dedicated to diabetes, was published in 2022 (and January 2023), with 25 chapters and over 250 authors (global distribution, early career and senior, diverse professional background, and persons with diabetes). The editor (Maria Craig), co-editors (Ethel Codner, Farid Mahmud, Loredana Marcovecchio, and Linda DiMeglio), guest editor (Joseph Wolfsdorf), and project manager (Leena Priyambada) deserve special thanks. ISPAD is currently collaborating with partners on the translation of the ISPAD 2022 CPCG into various languages to facilitate access.

Over the last year, the inclusion of Diabetes Advocates as members of our Society was promoted. Already for many years the Articles of Association have included this membership category. The contribution of persons with diabetes in scientific societies, guidelines, in research and drug development has become essential. We are looking forward to their ongoing input in our Society.
When the first positive signs of control of the pandemic were observed, the war in the Ukraine provided a different humanitarian crisis.

ISPAD collaborated with organizations that are trained to deliver care in regions with humanitarian crises. Some resources were developed in collaboration with the membership for all those who had to leave their country. It was encouraging to see so many people ready to act, but it was disheartening to learn that another region of the world was at war. Our assistance should be (made) available to all those suffering from humanitarian crises in conflict zones wherever and whenever it is required and possible.

Two and a half years have flown by. It was fantastic to meet face to face again in Abu Dhabi for those who could join and where a limited virtual program could be offered.

It has been very special for me to fulfil the role of president of ISPAD. I extend my thanks to an extraordinary Executive Board, an Advisory Council with very active Committees, and to Sylvia Lion advisor on corporate relationships. The JENIOUS Group with its creative initiatives and dedication is incredible and highly important for this society. The input and ongoing work of K.I.T. Group is highly appreciated. Without the support of members, foundations, and corporate partners ISPAD would not be able to function as it does. Thank you all very much for what has been done and has been achieved. This report is not exhaustive with respect to all ISPAD partners but highlights some new and some existing partnerships.

It goes without words that the collaboration and friendship within the executive board are essential for the work ISPAD does. Kim, Jamie, Lars, Eduardo, David and Roque: thank you. I’m certain that ISPAD is in great hands to fulfil the tasks our Society has set out to achieve.

ISPAD friends from the past and new ones from recent years: I’m grateful for your dedication to our common goal.

Last but not least I would like to thank the persons with diabetes and their caregivers, worldwide, who are our inspiration and who deserve our ongoing admiration for the job they are doing on a 24/7 basis.

Carine de Beaufort
President 2020-2022
V. ISPAD Secretary General’s Report

by Jamie Wood

July 1, 2020 – December 31, 2022 – An amazing two and a half years in which ISPAD members around the globe continued our work despite a global pandemic, international conflict and war, and natural disasters. Despite these challenges we have seen ISPAD grow in the size and diversity of its membership and the extent of its global reach with ISPAD webinars, endorsed conferences, fellowships, Science Schools. During this time frame we transitioned from having to cancel events (Science Schools for Physicians 2020 and Science School for Health Care Professionals 2020), to 100% virtual activities (Science Schools 2021 and Annual Conference 2020 and 2021), and then back to in person activities. Being back together in person in Abu Dhabi for our Annual Conference was an incredible feeling!

The ISPAD newsletters, website and this report highlights the impressive and critical work by ISPAD over the past two and a half years in collaboration with our many partners worldwide. We also thank the many professional organizations with whom ISPAD collaborates. In addition, our corporate partners have generously contributed again to the mission of ISPAD to allow for additional work to achieve our goals. When I think of ISPAD I think of teamwork, hard work, dedication, friendship, and collaboration. Together the ISPAD Community continues to achieve its vision, the creation of:

*A better world for children, adolescents and young adults with diabetes.*

**Organization**

During the virtual general meeting in 2020, new members were elected to the Advisory Council: Jenny Couper, Klemen Dovc, Paul Wadwa, and Zdenek Sumnik. All leaving members of Council, Anna Lindholm Olinder, Linda Anne DiMeglio, Asma Deeb, and Thomas Kapellen, were gratefully acknowledged for their contributions. During the virtual general meeting in 2021, new members were elected to the Advisory Council: Brynn Marks, Tiago Jeronimo, Rade Vukovic, and May Ng. All leaving members of Council; Farid Mahmud, Ingrid Libman, Declan Cody, Sarah Ehtisham, and Katarzyna Gajewska, were gratefully acknowledged for their contributions. During the general meeting in Abu Dhabi in 2022, new members were elected to the Advisory Council: Leena Priyambada, Agata Chobot, Sheryl Salis, and Cari Berget. All leaving members of Council, Roque Cardona-Hernandez, Julia von Oettingen, and Helen Phelan were gratefully acknowledged for their contributions.

The Advisory Council does a tremendous amount of work through eight committees: Communications, Fellowships, Roving Reporters, Prizes, Membership, Abstracts, Education and E-Learning. We also rely on many ISPAD members who volunteer on the various committees. A special thanks to Past President Joseph Wolfsdorf who has Chaired the E-Learning Committee. During this time frame we also had a temporary committee to plan ISPAD’s recognition of the 100th anniversary of the discovery of insulin in 2021-2022, led by Roque Cardona-Hernandez. ISPAD published its first comic book.
I would like to acknowledge the excellent work and close collaboration with our management group, K.I.T. Group GmbH. Without their management of the Society’s affairs and organizational help for the Conference, ISPAD would not thrive as it currently does. Additionally, on behalf of the Executive Committee I extend a special word of appreciation to Sylvia Lion, a long-time ISPAD member and supporter, who has generously donated her time and expertise to help us develop a more robust corporate strategy and financial accounting system with the goal of keeping our society healthy as we expand for the future.

The ISPAD Executive Board appointed me as their first Director of Communications in 2017. This honor was passed on to Eduardo Calliari in 2020, and then to Roque Hernandez in 2022. Under their leadership ISPAD's Communication Strategy has become more sophisticated with a far-reaching impact. The number of posts, tweets, followers, and impressions have grown each year.

ISPAD has worked very hard over the last several years with various patient advocate groups. ISPAD feels that the patient's voice is critical to any successful society. ISPAD recognizes established Patient Advocates as full ISPAD members. In addition, we have people with diabetes on our Annual Conference planning committee, Roving Reporters, and Clinical Practice Consensus Guideline Chapters. We held dedicated Patient Advocate Symposia at both the 2021 and 2022 Annual Conferences.

Lastly, I would like to sincerely thank my friends and colleagues who have served with me on the Executive Board, Past Presidents Kim Donaghue and Carine de Beaufort, President David Maahs, and Treasurer Lars Krogvold. Their contributions and dedication to ISPAD are enormous and numerous. I look forward to serving with the next President, Secretary General Elect and Treasurer Sabine Hofer. ISPAD’s future is bright.
Prizes 2021

Selection of the best candidates for prizes in 2021 was a difficult task due to the high quality of the candidates. The following outstanding persons received their award at the 2021 Virtual Annual Conference and were recognized in person at the 2022 Annual Conference.

**ISPAD Prize of Achievement 2021**

Kindly supported by Eli Lilly

![Lilly](image)

**Thomas Danne, Germany**

Prof. Dr Thomas Danne is the Director of the Department of General Pediatrics Endocrinology/Diabetology & Clinical Research at the “AUF DER BULT” Hospital for Children and Adolescents, Hannover Medical School, Germany, which is the largest pediatric diabetes center in Germany. He trained at the Free University Berlin Children’s Hospital in Berlin mentored by ISPAD Founding Member and Prize Winner Bruno Weber and was Consultant Pediatrician at the Charité Children’s Hospital of the Humboldt University Berlin. He is a former Research Fellow of the Joslin Diabetes Center of Harvard Medical School in Boston. Presently he is appointed as Chairman of the SWEET-registry and work-package leader of the INNODIA-project, a consortium to fight type 1 diabetes.

In 2000 he organized the inaugural ISPAD Science School for Physicians and has served as Secretary-General of the International Society for Pediatric and Adolescent Diabetes (ISPAD) from 2004 - 2008 and as President 2008 - 2010. Also, he is the Past-President of the German Diabetes Association (DDG) and the German Diabetes Aid (diabetesDE).

He has been awarded the “Helmut-Otto-Medal” of the German Diabetes Association, the “Somogyi-Award” of the Hungarian Diabetes Association and the “Lifetime Achievement Award” of the International Diabetes Federation (IDF).

Dr Danne has published 280 peer reviewed papers (cumulative h-index 48), has been the Deputy Editor Europe of Pediatric Diabetes and is on the Editorial board of several journals and has contributed to several books. His research interests include basic and clinical research in pediatric diabetology with special emphasis on quality improvement through registers (HVIDORE, SWEET), new insulins, glucose sensors, insulin pumps and automated insulin delivery (DREAM).

**Watch the ISPAD Prize for Achievement 2021 video [here](#)!**
Angie Middlehurst, UK, Australia

Angie Middlehurst is a UK and Australian Registered Pediatric and General Nurse, and Diabetes Educator. Angie became a member of ISPAD in 1995, following employment at Diabetes Australia-NSW as the first Pediatric Diabetes Educator. During her tenure there, and at The Children’s Hospital at Westmead, Angie developed many age-appropriate written and visual education resources, including a website specifically for children with diabetes and their families, and the DVD “Professor Bumblebee’s Guide to Type 1 diabetes”, translated into many languages, and still used globally. Angie worked locally, nationally and internationally to improve management of children and young people with diabetes at school, supporting children, families and school staff. She was co-author of the 2018 ISPAD Position Statement on Management of Children in School, and a consultant for the initial IDF KiDS Project. Angie was a faculty member for the International Diabetes Federation Young Leaders Conferences in Melbourne and Vancouver, and still maintains contact with many young leaders. Angie also conducted bi-annual diabetes camps; assisted in introducing an ambulatory care clinic; was involved with implementing transition from pediatric to adult care and writing national guidelines.

From 2011-2018, Angie was Deputy Manager and Education Director for the Life for a Child (LFAC) Program, expanding the Education website to include resources in multiple languages; co-authoring the Pocketbook and Camp Guidelines for less-resourced countries; liaising with partners in supported countries regarding collection of local data, and compilation of registers; co-authoring research papers; developing a DKA Awareness Campaign with posters in multiple languages; presenting at international conferences; conducting site visits while also acting as a faculty member for education workshops in Fiji, Bangladesh, Vietnam, Sri Lanka, Jamaica, Cayman Islands, Tanzania, Uzbekistan, Bangalore and India, many in conjunction with ISPAD. Since leaving LFAC, Angie has continued her passion to improve the quality of life for children with diabetes and their families, particularly in less-resourced countries, by volunteering for many international organisations: ISPAD; APPES; IDF; LFAC; IFL; A4D; CDiC; CLAN and PenPals United USA.

Angie was a founding member of the sub-committee for developing an accredited diabetes educator training course for allied health professionals in Africa, endorsed by ISPAD and ASPAE.

She is a co-author of the chapter on Limited Care for the ISPAD Consensus Guidelines 2022, and a member of the ISPAD E-Learning Committee. Angie is also the lead, on behalf of ISPAD, for the collaboration between ISPAD and IDF for the KiDS Project.

Watch the ISPAD Lestradet Prize for Education and Advocacy 2021 video [here](#)!
Osagie Ebekozien, USA

Dr Ebekozien is the Vice President of Population Health and Quality Improvement at the T1D Exchange. In this role, he serves as the Principal Investigator for a multi-center learning health system with over 40 centers actively implementing innovative practices to improve pediatric diabetes care. He grew the network from twelve to forty-one centers. Furthermore, he led the network to develop several pioneering programs, including the T1D Improvement Online Portal for data benchmarking and the T1D COVID19 Surveillance program, which resulted in significant insights used by national policies and improved pediatric diabetes clinical care. In addition, he developed a new framework that incorporates implementation science, quality improvement to advance health equity in diabetes management.

He is an Adjunct Assistant Professor of Population Health at the University of Mississippi Medical Center. He teaches graduate-level courses on population health, quality improvement, and health equity. He also serves as an Associate Faculty with Ariadne Labs, contributing to innovative population-based global projects.

As one of the Lead Faculty for the Morehouse University School of Medicine National Diabetes Health Equity Collaborative, he coached different organizations to reduce inequities in health outcomes for patients with diabetes.

Dr Ebekozien's innovative approach uses real-world evidence, collaborative quality improvement, health equity, and implementation science principles to transform systems and advance care practices. He has delivered over 70 conference presentations with numerous invited keynote and plenary sessions. In addition, he has authored/co-authored over 25 peer-review publications, with most of them as a first or senior author. He is a member of the Journal of Clinical Outcomes Management Editorial Board and the Medtronic Diabetes Health Equity Advisory Board.

Dr Ebekozien previously led the Office of Quality Improvement at Boston Public Health Commission. In this role, he advanced the culture of performance management and informatics. He led strategic initiatives for the city of Boston, including the implementation of major population-based programs in partnership with Boston-based Hospitals. In addition, he led the city of Boston to achieve its first National Public Health Accreditation and strengthened epidemiological advancement in diabetes management.

He is a graduate of the University of Ibadan and Harvard School of Public Health. Several major news media networks like ABC News have featured Dr Ebekozien and his work. Additionally, he has received multiple awards, including the 2019 NACCHO National Model Practice Award, the 2018 City of Boston HHS Service Excellence Award, the 2015 Tufts Foundation Innovation Award, and the 2011 NDDC Merit Award.

Watch the ISPAD Prize for Innovation in Pediatric Diabetes Care 2021 video [here](#)!  

ISPAD Activity Report 2020 - 2022
Dr Torben Biester is a pediatric diabetologist from Hannover, Germany. After studying medicine at Hannover Medical School and one year of internal medicine, he started his pediatric training at the Children’s Hospital AUF DER BULT in 2009 becoming a board-certified pediatrician in 2014 and later specialized in emergency medicine (2015) and diabetology (2016).

In addition to his research and clinical work in the hospital, he works as an emergency physician in German emergency ambulance service. From entering his pediatric training, he became a member in the group of Professor Thomas Danne and Professor Olga Kordonouri taking care of children, adolescents and young adults with all forms of diabetes. For four years he has got his own outpatient clinic.

In 2021 he submitted his promotion to receive the “venia legendi” at Hannover Medical School with a habilitation thesis entitled „Use of continuous glucose monitoring in children and adolescents with type 1 diabetes leading to automatic insulin delivery“. His scientific work started with his doctoral thesis about the pharmacokinetics of insulin degludec in children and adolescents, where he got in touch with ISPAD presenting the results of his thesis at the 37th Annual Meeting in Miami 2011. In 2014, he participated in ISPAD Science School for Physicians at the Joslin Diabetes Center in Boston, where he found friends that all became a proud part of the ISPAD JENIOUS group.

Over time, he was investigator and principal investigator in more than 50 clinical trials. As a member of the international “DREAM” consortium he worked together with teams from Ljubljana, Slovenia and Petah Tikvah, Israel on the development of closed loop systems, being part of publications in NEJM, Lancet, DOM and Pediatric Diabetes. A more recent focus of his research has been the adjunctive therapy to insulin in type 1 diabetes. Based on the results of a study on the pharmacokinetics of the SGLT2 inhibitor dapagliflozin in adolescents and young adults, he also investigated the combination of an SGLT2 inhibitor with a full-closed loop AID-system. He was in the writing group of the recent Consensus paper on Targets for Continuous Glucose Monitoring and has published more than 40 papers in peer-reviewed journals.

Currently, he is a member on the Editorial board of Diabetes, Obesity and Metabolism and serves as Deputy Speaker of the German Pediatric Diabetes Working Group. Since 2021 he is a panel member of the European Union Commission for new medical products in diabetology.

Watch the Young Investigator Award 2021 video [here](#)!
Jeff Hitchcock was the president and founder of Children with Diabetes, Inc. (CWD). CWD offers education and support to families living with type 1 diabetes through its website and its conferences. Its renowned Friends for Life Orlando conference is held each year at Disney World in Orlando, Florida, hosting thousands of people from across the US and many other countries for the largest family-focused type 1 diabetes event in the world.

Jeff founded Children with Diabetes in June of 1995 to share his family’s experiences in raising a child with diabetes. Marissa, Jeff and Brenda’s first child, was diagnosed in September 1989 at the age of 24 months. Marissa graduated with a bachelor’s in nursing from the University of Cincinnati in May 2009, married Adam in 2012, earned her CDE (now CDCES), and welcomed a healthy baby boy into the world in September of 2013. In the fall of 2017, Marissa and Adam welcomed a baby girl into their family. Marissa and her family live in the Cincinnati area, and she serves as the Clinical Director for Children with Diabetes.

In addition to his work at Children with Diabetes, Jeff is involved in programs with the T1D Exchange, ISPAD, various national advocacy groups, and is a sought-after speaker at national and international conferences on the impact of type 1 diabetes on families. He serves on the Board of Directors for the Diabetes Patient Advocacy Coalition (DPAC) and Beta Bionics.

Prior to his work at Children with Diabetes, Jeff served in US national intelligence and the private sector focusing on high technology solutions to national problems. After his work in the intelligence sector, Jeff worked briefly at LEXIS-NEXIS and at a digital solutions company that was part of Pearson plc, helping to bring educational content online. Children with Diabetes is an Ohio-based 501(c)(3) non-profit that provides unbiased, science-based education and support to families living with type 1 diabetes. To learn more, visit childrenwithdiabetes.com

Watch the ISPAD Hero Award 2021 video here!
Prizes 2022

Selection of the best candidates for prizes in 2022 was a difficult task due to the high quality of the candidates. The following outstanding persons received their award at the Annual Conference:

ISPAD Prize of Achievement 2022

Kindly supported by Eli Lilly

Kim Donaghue, Australia

Dr Donaghue graduated in Medicine (1979) from the University of Sydney. She was a Harvard Research Fellow at Massachusetts General Hospital in Boston and a Clinical Research Fellow at Royal Alexandra Hospital for Children in Sydney. In 1990 she was appointed as a Staff Endocrinologist at the Children’s Hospital at Westmead and established the Diabetes Complications Assessment Service. She was awarded her PhD (2001) from the University of Sydney on the role of puberty in the development of diabetes complications. She led the Diabetes Service from 2004-2016; and was CoHead of Institute of Endocrinology and Diabetes 2010-2016. She was appointed as a Conjoint Professor in Child and Adolescent Health at the University of Sydney in 2010.

Her H-index is 52 with over 200 publications, primarily in diabetes complications. She is currently a Chief Investigator and Member of the Steering Committee of two major international trials to reduce complications from type 1 diabetes.

She has a major interest in Education and Evidence-based Medicine. She was inaugural Chair of the Pediatric Endocrinology Curriculum for the Royal Australasian College of Physicians. She was one of four senior Editors of the ISPAD Consensus Guidelines for Pediatric Diabetes in 2006-9, the first to use graded levels of evidence. She was a founding member of the Australasian Diabetes Data Network in 2012.

She gave the Plenary Lecture on “The Future of Childhood Diabetes” in November 2018 for the IDF Western Pacific Meeting in Kuala Lumpur; and at the IDF Biennial Meeting in December 2019 in Busan, Korea. She was awarded the Norman Wettenhall Prize for Research and Innovation by the Australasian Pediatric Endocrine Group (2015) and a Lifetime Achievement Award by the Australian Diabetes Society (2022).

She chaired the “Big Little Changes Working Group” for Management of type 1 diabetes during COVID with JDRF and BeyondT1 in 2020. She is currently cochairing a Working Group on insulin submission for the WHO Essential Medicines List 2023. Dr Donaghue has been a foundation partner on behalf of ISPAD for the development of the T1D Index with JDRF, IDF, LFAC and others.

Watch the ISPAD Prize for Achievement 2022 video here!
Prof. Dr. rer. nat. Karin Lange is the Head of the Medical Psychology Unit at the Hannover Medical School, Germany. Her doctoral degree is in Psychology.

Since 1990 she has been cooperating with the Diabetes Centre for Children and Adolescents at “Kinderkrankenhaus AUF DER BULT Hannover”.

Since 1985 Karin Lange has been pursuing an interdisciplinary diabetes research program linking psychology, diabetology, and health services research. Focusing on type 1 diabetes mellitus, her research interests include psychological and behavioral aspects of several other chronic diseases (e.g. obesity, PKU, asthma, cystic fibrosis, type 2 diabetes or rare diseases like cystinosis or lysosomal storage diseases). Together with colleagues from several pediatric clinics nationwide she developed structured education and psychological support programs for families of affected children. As a member of the EU-CDEC project team she designed European standardized, accredited training for diabetes HCPs.

She is the lead author of nationwide diabetes-education programs for children, adolescents, and their parents, all of which have been evaluated and certified in the DMP Type 1 (Disease Management Program Type 1 Diabetes). Currently a structured pediatric CGM-education program has been evaluated and published.

Karin Lange is an ISPAD member for more than 20 years and is particularly committed to the education, participation and mental health of young, e.g. as one author of the ISPAD Clinical Practice Guideline Compendia in 2014, 2018 and 2022: Diabetes education. She is also a founding member of the international SWEET initiative, which advocates for equal, high-quality care for all children with diabetes worldwide. Here she focuses on the issues of quality of life, mental health and patient reported outcomes, especially in association with new diabetes technologies. Furthermore, she is responsible for the psychological screening on parents’ emotional well-being and burden due to the diagnosis of multiple diabetes-specific antibodies or genetically elevated risk of type 1 diabetes (GPPAD).

Karin Lange has published more than 100 peer reviewed papers and has contributed to several books for HCP as well as for people with diabetes.

Watch the ISPAD Lestradet Prize for Education and Advocacy 2022 video here!
Charles Toomey is the Co-Founder of Action4Diabetes (A4D) which was established in 2015, initially to address the plight of young people with Type 1 Diabetes in Myanmar. Subsequently A4D has expanded its footprint to cover Cambodia, Laos, Thailand, Malaysia and Vietnam, providing a range of tailored programmes. These include provisions of free insulin, and blood glucose equipment, patient, family and HCP education, running Diabetes Family camps and educational and vocational scholarships for young people with Type 1 Diabetes. In a recent innovation, A4D have launched the first ever digital support platform in Southeast Asia, ‘HelloType1’ to provide comprehensive local language content, all about Type 1 Diabetes to the T1D community, including patients, care givers and HCPs. HelloType1 is presently available in Khmer and Vietnamese, and will, in due course, be launched across other countries in Southeast Asia.

Charles has lived and worked in Asia for the last 22 years, and has a 35-year career founding, building and leading business operations across multiple geographies. This experience has been key to establishing and scaling the way in which A4D operates, which is in a highly cost-effective manner, leveraging local in country resources, and closely monitoring and tracking execution and deliverables, embedding governance, and ensuring impact and the delivery of meaningful outcomes. Another key ingredient to the success of A4D is that of partnership. A4D looks to actively partner with other key stakeholders in the ecosystem at a country and regional level, who share common aims and values, such as local HCPs, Medical Associations, Patients Associations, Pharmaceutical and Medical Device companies, Distributors, Logistics providers, and other NGOs.

Watch the ISPAD Prize for Innovation in Pediatric Diabetes Care 2022 video here!

"Jerry Gore is an exceptional example of a person who has achieved excellence in mountaineering, while at the same time having Type 1 Diabetes. In addition, he has demonstrated dedication and success in helping and motivating people with diabetes in the economically developing and developed worlds!"  
Sir Chris Bonington CVO, CBE, DL

Jerry started his diabetes advocacy campaign within two years of his diagnosis, with a front cover shot and article entitled “Mountains, inspiration and conquering diabetes” in the March 2004 edition of Diabetes Voice (IDf). Today Jerry is the only person with Type 1 Diabetes to open new routes on six of the World’s seven continents. He is the only Himalayan Mountain Guide with T1D. After gaining the UK speed record for the North Face of The Eiger he was made an IDF Blue Circle Champion in 2015. Since 2004 he has completed more than 20 JIC’s (Jerry’s Insulin Challenges - extreme mountaineering and cycling challenges) and has raised well over U$D 500,000 to support young children with T1D.

Since his T1D diagnosis, Jerry's personal mantra has always been “Diabetes is NOT an excuse".
Jerry Gore is also the Co-Founder of Action4Diabetes (A4D), established in 2015, to give health and hope to the Type 1 Diabetes community initially in Myanmar. Today, A4D’s footprint now also covers Cambodia, Laos, Thailand, Malaysia, Indonesia and Vietnam. A4D has three areas of focus:

**A4D Medical Support**
Since 2015 A4D has provided 35,000 insulin cartridges, enabled 1.7 million glucose tests, conducted 1,400 HbA1c tests, and provided continual T1D support to 700+ young people with T1D

**Healthcare Professional Support**
- A4D Webinars: A free continuous T1D education resource for HCPs in South-East Asia (SEA).
- HCP T1D Network meetings: A cross-country network to exchange knowledge, enhance skills, facilitate sharing of best medical practice, and strengthen SEA HCP collaboration for T1D.
- Sponsored Doctors: A4D supports junior doctors to assist in diabetes clinics at selected partner hospitals in Myanmar and Cambodia.

**Type 1 Education & Awareness**
- Hello Type 1 (HT1). This is the first online platform designed to make medical advice about managing T1D accessible in Asia for Caregivers, HCPs and Patients
- A4D Diabetes Family Camps. Since 2016, A4D has run 16 Diabetes Family Camps, for 1200+ participants across five countries
- ASPIRE: This programme provides scholarships for further education and training for young people with T1D from low-income households.

One of the key ingredients to the success of A4D is that of partnership. A4D continually looks for strategic partners and key stakeholders at a country and regional level.

**Watch the ISPAD Prize for Innovation in Paediatric Diabetes Care 2022 video here!**

**ISPAD Young Investigator Prize 2022**

Kindly supported by Medtronic

**Ananta Addala, USA**

Dr. Ananta Addala is a pediatric endocrinologist and physician scientist at Stanford University addressing disparities in pediatric type 1 diabetes management and outcomes. As a physician with a background in pediatric endocrinology, epidemiology, and behavioral health, she aims to build an evidence-based approach to addressing T1D disparities by systematically evaluating youth-, family-, provider-, and system-level barriers to optimal diabetes care in youth from low socioeconomic and racial/ethnic minority groups.

Dr. Addala received a bachelor's in biochemistry from the University of California, Santa Cruz and a Master's in Public Health from Boston University. She received her medical degree from the University of New England, pediatrics training from Los Angeles County Hospital, and endocrine training from...
Stanford University. She has been funded Maternal Child Research Institute and now is funded by NIDDK K23 to understand and address disparities in pediatric diabetes technology access and utilization.

To date, Dr. Addala's publications have demonstrated that the disparities in pediatric T1D by socioeconomic status are worsening in the US, provider bias against public insurance is common, and public insurance mediated interruptions to diabetes technology adversely impact glycemic outcomes. She has also been leading the efforts to improve justice, equity, diversity, and inclusion in research at Stanford University through her leadership at Stanford Pediatrics Advancing Anti-Racism Coalition and as the co-chair of TrialNet's Underrepresented Minorities Outreach Committee.

Watch the Young Investigator Award 2022 video here!

**ISPAD Hero Award 2022**

Oleg Novikov, Ukraine

Oleg Novikov, a young man from Ukraine, who works in Austria as a medical software designer in the field of diabetes facilitated the delivery of thousands of kilograms of diabetes supplies from Insulin for Life (IFL) to thousands of people, including children and adolescents during the war in Ukraine.

He also facilitated the delivery of essential medicines for children with congenital adrenal hyperplasia. Taking leave from his work he verified diabetes care needs and the need for other medical aid. He developed an extensive network of Ukraine clinicians, medical associations, Government officials, aid organizations, and volunteer drivers.

He collected shipments from IFL nodes in Austria, the Netherlands, Australia, and the USA from Customs and Couriers, sorted and packed them, and arranged volunteer drivers and logistic chains to take shipments to many areas in Ukraine. He worked with delivery teams, and paid delivery fees reimbursed by IFL and Spare a Rose campaign. Investigated the situation on the ground, confirmed deliveries, and provided photos and reports.

Oleg also provides advice to the IFL network and participates in meetings with other aid organizations, including the WHO, UN, and Mates4Kids. He closely works with several grassroots NGOs in Vienna that were created in response to the war. Most notably “Vienna Mission for Ukraine” and “YOUkraine”.

In natural or man-made disasters large aid shipments for diabetes care from organizations such as Direct Relief and the UN often take weeks to arrive, and their distribution can take time and not cover all areas, particularly occupied or recently emancipated areas.

People with Type 1 diabetes who have lost their medicines cannot wait weeks. Oleg enabled deliveries of essential diabetes supplies, including insulin in the first weeks of the war and he continues to facilitate deliveries to areas in great need.

Outside of disaster response, Oleg is working on a “Diabetes Cockpit” mobile application for T1 CGM users, intending to bridge the gap between their data, daily habits, and medical outcomes. Learn more at: https://cockpit-app.com/

Watch the ISPAD Hero Award 2022 video here!
Fellowships 2020-2022

Allan Drash Clinical Fellowships 2020-2022
Due to exceptional support from JDRF, ISPAD was able to award ten Allan Drash Fellowships per year. Full reports of the fellows clearly show their impact, improving clinical experience and changing the way local care was organized on their return to their country of origin.

2020: Peerzada Ovais Ahmad, India. Click here to read the report
        Nouran Salah, Egypt. Click here to read the report
        Yasmine Abdelmeguid, Egypt.
        Adele Bodieu Chetcha, Cameroon.
        Natasha Yaneva, Bulgaria.
        Manisha Gupta, India. Click here to read the report
        Apoorva Gomber, India. Click here to read the report
        Maria Teresa Onetto, Chile.
        Rakesh Kumar, India. Click here to read the report
        Mysterline Joseph, Haiti.

2021: Regina Duperval, Haiti. Click here to read the report
        Eren Er, Turkey. Click here to read the report
        Ghaisani Fadiana, Indonesia
        Deepika Harit, India
        Ahmed Hassan, Egypt. Click here to read the report
        Kaisun Nesa Lesa, Bangladesh
        Ankita Maheshwari, India
        Santosh Pokhrel, Nepal. Click here to read the report
        Sheryl Salis, India. Click here to read the report
        Sherline White, India

2022: Muzna Arif, Pakistan
        Moomin Hussain Bhat, India
        Emine Ayça Cimbek, Turkey
        Hiba Elshafie, Sudan
        Elif Eviz, Turkey
        Berna Eroğlu Filibeli, Turkey
        Sara Gafar, Sudan
        Erdal Kurnaz, Turkey
        Marzhan Rakhimzhanova, Kazakhstan
        Prusha Mohammed Salih, Iraq

View testimonials from past Allan Drash Awardees here.

JDRF-ISPAD Research Fellowships 2020-2022
Again, due to the generous support and partnership of JDRF, we were able to award 4 research fellowships each year. One of the 4 research fellowships was awarded to the best Science School for Physicians presentation at the annual Science School and voted upon by the Science School faculty including JDRF representation. The additional 3 research fellowship awards were granted thanks to the generosity of JDRF after evaluation by the ISPAD Fellowship Committee.
2020: **Elisa Giani**, Italy. Click [here](#) to read the progress report
**Christine March**, US. Click [here](#) to read the progress report
**Caroline Schulmeister**, US. Click [here](#) to read the progress report
**Dessi Zaharieva**, US. Click [here](#) to read the progress report

2021: **Vanessa Jewell**, US. Click [here](#) to read the progress report
**Claudia Piona**, Italy. Click [here](#) to read the progress report
**Rachel Wasserman**, US. Click [here](#) to read the progress report
**Emilia Kowalczyk**, Poland. Click [here](#) to read the progress report

2022: **Katarina Braune**, Germany
**Timothy Foster**, US
**Peerzada Ovais Ahmad**, India
**Yempabou Sagna**, Burkina Faso

For additional details visit the website: [http://www.ispad.org/?page=ISPADFellowships](http://www.ispad.org/?page=ISPADFellowships)

**FID-ISPAD Research Fellowship 2021-2022**
Due to the generous support of the Fondazione Italiana Diabete (FID) a new research fellowship grant was created in 2021. The aim of this grant is to support diabetes research that furthers progress towards the cure of diabetes.

2021: **Ki Wook Kim**, Australia Click [here](#) to read the report.

**Science**
Our Annual Conference is one of the most important assets of the Society, with scientific highlights as well as many occasions to discuss during and outside of meeting hours and to develop new contacts and collaborations. The Annual Conferences in 2020 and 2021 were held virtually, and the 2022 Annual Conference was held in person in Abu Dhabi.

**ISPAD 2020 – 46th Annual Conference**

[Image]

Website: [https://2020.ispad.org/](https://2020.ispad.org/)

Convenor: Farid Mahmud, Endocrinologist and Clinician-Investigator at the Hospital for Sick Children in Toronto, Canada.

Motto: Connecting, Collaborating, Caring, A better world for children, adolescents and young adults with diabetes.

Stats:
1,287 Attendees
213 Abstracts submitted

Highlights Report:  

Authors: Brynn E. Marks, Soren Harnois-Leblanc, Sze May Ng, E. Melissa Perez-Garcia, Peerzada Ovais Ahmad, Sara Adhami, Steve Vassili Missambou Mandilou, Lauren McClure Yauch, Sarah Ehtisham

ISPAD 2021 - 47th Annual Conference

Website: https://2021.ispad.org/

Convenors: Zdeněk Šumník, MD, PhD, Department of Pediatrics, Charles University and Motol University Hospital

Motto: Bridging the Distances

Stats:
1,414 Attendees
309 Abstracts submitted

2021 ISPAD Annual Conference Highlights

Report:  

Authors: Yasmine Elhenawy, Sara Adhami, Yasmine Abdelmeguid, Peerzada Ovais Ahmad, Paula Chinchilla, Declan Cody, Jody Grundman, Steve Vassili Missambou Mandilou, May Ng, Jose Antonio Orozco, Melissa Perez-Garcia, Klemen Dovc, Sarah Ehtisham
ISPAD 2022 48th Annual Conference

Website: https://2022.ispad.org/

Convenors: Prof. Asma Deeb, Chair of Pediatric Endocrinology, Sheikh Shakhbout Medical City, Professor of Pediatrics, Khalifa University, Abu Dhabi, ASPED President

Motto: From illness to wellness in childhood diabetes

Stats:
1,058 Attendees (781 Face to Face, 277 Virtual)
369 Abstracts submitted

2022 ISPAD Annual Conference Highlights
Authors: Sze May Ng, Helen Day, Jody B. Grundman, Peerzada Ovais Ahmad, Maja Raicevic, Tinotenda Dzikiti, Nancy Katkat, Anju Jacob, Marisa Ferreira Clemente, Hussain Alsaffar, Yasmine Ibrahim Elhenawy, Yasmine Abdelmeguid, Klemen Dovc

Oral Presentations, Abstracts & ePosters from all conferences can be viewed on ISPAD’s Resource Platform at: http://medialibrary.ispad.cyim.com/ for those who could not attend in person to be informed.
Pediatric Diabetes was our Society’s official journal from 2000 to 2023. Dr Phil Zeitler succeeded founding Editor-in-Chief Mark Sperling as Editor-in-Chief in 2017. Current Deputy Editors are Fergus Cameron and Sabine Hofer. Because the journal’s ownership was recently transferred from Wiley to Hindawi, ISPAD will no longer be associated with it. Because Hindawi has implemented publication fees for accepted manuscripts, ISPAD members should be aware that Pediatric Diabetes is no longer affiliated with ISPAD. We are working on new journal partnership opportunities for ISPAD, including the publication of our Guidelines, and we are optimistic about the future.

Education
The Science Schools for Physicians and for Healthcare Professionals are one of ISPAD’s most successful traditions. ISPAD is grateful for the financial support of the sponsors, Eli Lilly, Novo Nordisk, Medtronic, Ascensia Terumo and acknowledges with gratitude the passion and hard work of the conveners. In 2022, the JDRF has also pledged their support of both Science Schools. Unfortunately, neither Science School was able to happen in 2020 due to the COVID-19 pandemic.

ISPAD Science School for Physicians (SSP) 2021 - Virtual, May 2-6, 2021
(Convened by Chizo Agwu)

The 20th ISPAD Science School for Physicians was the first to be held virtually rather than in person. After recovering from the disappointment of being unable to hold it in the historic Shakespearean market town of Stratford-Upon-Avon in the United Kingdom due to the COVID-19 pandemic, the LOC and I sought to create the atmosphere of a virtual community while maintaining a high scientific content. There were 20 fellows and 4 Jenious mentors from all across the globe (Australia, New Zealand, USA, UK, Tanzania, Congo, Canada, Brazil, Colombia, Germany, Denmark, Poland, Bulgaria, Serbia, India, Egypt, Turkey, and Italy). The quality of research proposals was high and ranged from basic science to clinical studies and qualitative studies. The JDRF research fellowship was won by Dr Emilia Kowalczyk from Poland. The case presentations were all varied and really interesting, with the best-case presentation won by Dr Yasmine Mohamed Ashraf Saad Galal Mohamed Abdelmeguid from Egypt. The winning case presentation and runners-up are going to be adapted into the e-learning vignettes for our ISPAD-ESPE e-learning program.

Eli Lilly and Novo Nordisk have provided a sponsorship grant towards the costs for the technical platform, planning and costs associated with holding this meeting virtually.

ISPAD also gratefully acknowledges the support of JDRF towards the ISPAD-JDRF Research
Fellowship program. One fellowship was awarded to the best research project from the ISPAD Science School for Physicians.

More information can be found on:  
https://www.ispad.org/page/Reportfromthe20thISPADScienceSchoolforPhysicians

**ISPAD Science School for Physicians (SSP) 2022 - Prague, Czech Republic, May 22-26, 2022**

The 21st Science School for Physicians 2022 took place in Prague, Czech Republic, during May 22-26, under the motto: “Paving the way for future diabetes research”, convened by Dr. Zdeněk Šumník and Dr. Lenka Petruželková.

During the intensive 4-day scientific program, the school provided the most recent presentations from the 14 faculty members to 21 delegates from 16 nations and 5 continents, including Europe, Australia, Africa, Asia, North America, and Central America, along with 3 interactive workshops.

The attendees and faculty alike benefited from the intensive week of collaboration, interactions, and fantastic brainstorming, all while immersed in the lovely Prague atmosphere. We gratefully acknowledge the support and scientific contributions of our sponsors, JDRF, Eli Lilly, and Novo Nordisk. Finally, thanks to AMCA’s tireless administrative support, the week proceeded virtually flawlessly! THANKS!

**On behalf of the local organizers, Zdeněk Šumník & Lenka Petruželková**
17th ISPAD Science School for Health Professionals (SSHP), October 11-12, 2021 (Virtual)

14 participants from India, Italy, Poland, Mauritius, Haiti, Turkey, USA, Liberia and Nepal participated in this 2-day virtual workshop that focused on the development of research projects.

The workshop was held virtually for the first time ever due to the ongoing global Covid-19 pandemic. The participants represented a range of allied health backgrounds including nurses, psychologists, dietitians and social workers. Participants presented research projects with a wide range of ideas including improving pathways for transition to adult care, art therapy for children with diabetes (and cystic fibrosis related diabetes), improving postprandial glycemic control using low GI breakfast meals and a closed loop pump system, Neurocognitive performance in children with type 1 diabetes and HbA1c disparities in children from low socio-economic areas.

The 17th ISPAD SSHP faculty members included Megan Paterson (Nurse, John Hunter Children's Hospital Newcastle, Australia), Steven James (Nurse, University of the Sunshine Coast, Queensland, Australia), Timothy Skinner (Psychologist, Københavns Universitet Copenhagen, Denmark), Eda Cengiz (Physician, Yale University School of Medicine) and Sara Adhami (Dietitian, Dubai UAE).
18th ISPAD Activity Report 2022 - 2022

More information here: https://www.ispad.org/page/17thISPADSSHPReport

18th ISPAD Science School for Health Professionals (SSHP), October 10-12, 2022 (Abu Dhabi, United Arab Emirates)

12 participants from Australia, UK, Ireland, Poland, Holland, Kenya, Canada and Liberia took part in the 18th SSHP workshop which focuses on teaching research methodologies and developing research projects. The workshop welcomed allied health professionals from a variety of backgrounds including nursing, dietetics, social work and psychology.

Participants have presented research projects from a range of subject areas. Topics included the development of a psychology tool for young people with newly diagnosed diabetes; a survey to help identify challenging foods for dosing insulin; improvements in diagnosing and managing cystic fibrosis related diabetes; education for schools and after school care in Poland, dietetic resources for young people with type 1 diabetes and eating disorders and improving access to diabetes education and support to young people with diabetes in less resourced countries.

The 2022 ISPAD SSHP faculty was facilitated by Dr Megan Paterson (Diabetes Nurse, Diabetes Nurse, University of Queensland, Australia), Professor Timothy Skinner (Psychologist, Københavns Universitet Copenhagen, Denmark), Professor Eda Cengiz (Pediatric Endocrinologist, University of San Francisco, California USA) and Sarah Adhami (Diabetes Dietitian Dubai, UAE).
**JENIOUS**

**Juniors in Educational Networking and International Research Opportunities: United Sessions.** Their objective is to connect young ISPAD members to the Society, and involve them in Education, Networking, Research and Advocacy. One of the first initiatives has been the development of an evaluation tool of the Science schools with a focus on the SSP. Their findings were recently published in Pediatric Diabetes ([see article here](https://www.ispad.org/page/OtherISPADCourses)) Their role as mentors for the fellows in the SSP has been highly appreciated. They have conducted several innovative and collaborative research projects resulting in publications and presentations. Their intention is to create a unique, innovative platform to connect young physicians, residents, PhD students and other healthcare providers aged < 40 years is currently ongoing, fully endorsed by the ISPAD Executive Board. Their networking activities continue during ISPAD’s Annual Conference, where they will present their program for the coming years. The future success of ISPAD depends on the contributions of its young and dynamic membership. This initiative shows that ISPAD’s younger members are eager to be involved. We look forward to further collaboration with the JENIOUS group. Leadership of JENIOUS in the past years included: Klemen Dovc, Elisa Gianni, Tiago Jeronimo. Current JENIOUS leaders are Agata Chobot, Claudia Piona, and Laura Cudizio. A warm thanks to all JENIOUS members and leadership for moving ISPAD forward into the future. Elections will be held annually with each member serving a 3-year term and a new member joining each year.

**Various Courses in 2020-2022**

Different postgraduate courses were organized with the support of ISPAD or ISPAD members. One of the silver linings of the COVID-19 pandemic was the push to offer courses virtually, increasing the reach of ISPAD’s educational programs. Although for some of them official reports have been submitted, this is not yet the case for all. To ensure that training is offered where needed, but to prevent redundancy, we kindly request all members involved in these activities to keep us informed and to keep the membership informed. For this purpose, a special link has been created on the website, with information on the regulation around these postgraduate courses, the forms to submit before and after the course, but as well a dedicated form for those who agree to participate as faculty.

View listings of recent courses:

https://www.ispad.org/page/OtherISPADCourses
https://www.ispad.org/page/NonISPAD

To continue to offer postgraduate courses in many places around the globe, more tutors are needed who are fluent in different languages. If you are interested in organizing a postgraduate course or want to participate as a tutor, fill in the forms on the website, and check our current workshop guidelines, developed in close collaboration with Life for a Child (Angie Middlehurst and Graham Ogle). See the links listed under “Standard procedures for ISPAD postgraduate courses” here: [http://www.ispad.org/?page=ISPADPG](http://www.ispad.org/?page=ISPADPG). The Education Committee, under the leadership of Brynn Marks, has developed a process for ISPAD endorsement of educational conferences and courses: [https://www.ispad.org/page/ISPADEndorsement](https://www.ispad.org/page/ISPADEndorsement)

Life for a Child (LFaC)
The Life for a Child Program is an international aid program that provides life-saving support to children and youth with diabetes in developing countries. The Program works with different partners and established diabetes centres in these countries. These centres will be provided with medical supplies for clinical treatment and with diabetes education to the children and youth in their care. Eli Lilly supports the program with free insulin. The program has now reached its 22nd year and more than 46,000 children in 45 countries are currently supported by the Program. Their goal is to support 150,000 children in 65 countries by 2030. Different patient materials, translated in many languages are accessible on the LFaC website.

For many years, ISPAD has collaborated with LFaC in providing input for the educational materials for healthcare professionals (Pocketbook for health care professionals, faculty for postgraduate courses). To structure the set-up of post graduate courses, ISPAD developed in collaboration with LFaC a postgraduate course manual that is available on the ISPAD website.

The dedicated management, with Graham Ogle as Director, is based in Sydney, Australia. www.lifeforachild.org

Changing Diabetes in Children (CDiC)

This initiative of Novo Nordisk in collaboration with Roche, the World Diabetes Foundation (WDF) and ISPAD has as target to improve delivery of care to children with type 1 diabetes in resource-poor settings. www.novonordisk.com/cdic

As of December 2022, more than 41,000 children had been enrolled in 26 countries, more than 24,000 healthcare professionals had participated in training sessions in diabetes management, and more than 360 clinics have been formed.

ISPAD has been the partner in the education of health care professionals and the development of educational materials for these postgraduate courses. Patient, and health care professional educational materials have been translated into different languages (Hindi and Spanish are the newest contributions) and are freely available through the website. CDiC and ISPAD will be entering a new collaboration in 2023 to further expand the program.

ISPAD Clinical Practice Consensus Guidelines 2022 (CPCG)

ISPAD’s Clinical Practice Consensus Guidelines are the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes worldwide! Authors include experts from across the globe. The 2022 CPCG were just published in Pediatric Diabetes and are available here: https://www.ispad.org/page/ISPADGuidelines2022.

The development of the 2022 CPCG were led by Dr Maria Craig (editor-in-chief), and an editorial team of Drs Linda DiMeglio, Ethel Codner, Farid Mahmud, and Loredana Marcovecchio with senior editorial guidance from Past-President Joseph Wolfsdorf. For the first time, we had a Project Officer (Dr. Leena Priyambada) to support the editorial team and authors.
E-learning

E-learning has become a tool during meetings and has taken its place in new training curricula. Developing an e-learning tool from scratch is a complex and expensive task. On invitation by Professor Sten Drop, Rotterdam, who has developed the e-learning tool for pediatric endocrinology (ESPE), ISPAD has been developing the e-learning Diabetes modules, based on our Guidelines, and using the platform already developed by Professor Drop’s team. In addition, ISPAD created an e-learning committee chaired by Joseph Wolfsdorf. The committee has organized many successful webinars on timely topics: https://www.ispad.org/page/ISPADWebinars.

Access to the e-learning Diabetes modules is be offered through the ISPAD website, free to all members: https://www.ispad.org/page/ELearningPortal

Advocacy

Collaboration with other organizations

In the past two years, further collaborations with various scientific and patient organizations have been intensified to reach a wider population, prevent redundancy and to optimize outcomes.

American Diabetes Association (ADA)

www.diabetes.org

ISPAD and ADA continue to collaborate on many projects including the exchange of symposia at our Annual Conferences.

Australasian Pediatric Endocrine Group (APEG)

In 2015 ISPAD held for the first time a joint annual conference with APEG.

The contribution of APEG and its committees has been instrumental, and the conference was a huge success with many attendees.

www.apeg.org.au (now ANZSPED)

Arab Society for Pediatric Endocrinology and Diabetes (ASPED)
The collaboration with ASPED has been fruitful and has led to exchanges in the field of training in diabetes clinical care and research. The sixth ISPAD-ASPED postgraduate course was held in October 2022 in Abu Dhabi, UAE.

www.asped.net

**European Society for Pediatric Endocrinology (ESPE)**

Different projects continue in collaboration with ESPE such as the PETF(C)WA and the e-learning program. This will allow more healthcare professionals to learn about diabetes care, and to discuss how this could be reflected in the Guidelines. It should stimulate exchanges of best practices, to improve the outcome. Regular combined symposia are organized at the annual conferences of both societies. In addition, ISPAD leadership has agreed to support ESPE educational initiatives by providing faculty with specific expertise in pediatric diabetes.

www.eurospe.org

**Global Pediatric Endocrinology and Diabetes (GPED)**

GPED is an organization whose purpose is to provide development opportunities regarding pediatric endocrinology and diabetes and care for children with endocrine diseases in the developing world. Members include representatives of the different societies involved in pediatric endocrinology and diabetes. Regular newsletters are published and can be accessed through the link on the ISPAD website. Currently Jean-Pierre Chanoine has been re-elected as Secretary General. A member of the ISPAD executive committee will be part of the GPED executive to ensure further support and collaboration, where needed, to provide essential medicines such as hydrocortisone, fludrocortisone, etc. the places where these are still lacking. Julia von Oettingen is the ISPAD liaison to GPED.

www.globalpedendo.org

**International Diabetes Federation (IDF)**

The collaboration with IDF in the field of pediatric diabetes as well as the collaboration with LfaC has been summarized in the two MoU’s. During the biannual conference the ISPAD lecture is traditionally given by the ISPAD President. Further collaborative projects will be pursued with the focus on children with diabetes.

www.idf.org

**Juvenile Diabetes Research Foundation (JDRF)**

Collaboration with JDRF has been intensified over the last year. JDRF and ISPAD are proud to announce 4 annual Research fellowships, jointly sponsored by the two societies! These competitive grants of
25,000 USD will provide a fantastic opportunity to foster more high-level research in the field of pediatric diabetes. In addition, JDRF generously supports **10 Allen Drash Fellowships** per year. Lastly, JDRF is also supporting our two Science Schools. ISPAD is very grateful for this support and looks forward to continued collaboration in this very important endeavor. Our mutual goal is to continue to promote further interaction with symposia and training of young researchers. Lastly, JDRF in collaboration with ISPAD, LFaC, IDF, and Beyond Type 1 launched the T1D Global Index in Sept 2022 – a data simulation tool that measures and maps the human and public health impact of T1D. [https://www.t1dindex.org/](https://www.t1dindex.org/)

**Future Conference**

**ISPAD 2023 - 49th Annual Conference**

**Location:** Rotterdam, The Netherlands

**Dates:** October 18-21, 2023

[https://2023.ispad.org/](https://2023.ispad.org/)

---

**Conclusion**

2020-2022 have been incredibly successful years during which ISPAD and its membership emerged from the COVID-19 pandemic stronger and more united to achieve our vision. We have accomplished great things together and each year the world is a little better for children, adolescents and young adults with diabetes. I sincerely express my gratitude towards KIT, our corporate partners, other organizations and societies that we partner with, and all ISPAD members, especially our Advisory Council Members and Committee Volunteers.

*Jamie R. Wood*

ISPAD Secretary General 2020-2024
VI. ISPAD Communications Report

by Jamie Wood and Roque Cardona-Hernandez

The role of the Director of Communications is to oversee the communication between ISPAD Leadership, ISPAD membership, and the worldwide diabetes community via our website, social media, emails, and newsletters. The Director also makes liaisons between the Executive Board and K.I.T. Group.

The present report brings statistics and comments about the performance registered on the ISPAD Website, Newsletters and Social Media channels in the period from July 1, 2020, to December 30, 2022.

This period of two and a half years was very challenging, and social distancing pushed ISPAD Communications forward, enabling us to keep in close contact with our members despite the difficulties.

The initial response to the COVID Pandemic was the creation of the COVID Forum on our website, and many other actions followed, directed to reassure and orientate members about this new disease and diabetes management.

The ISPAD Annual conferences had to be virtual in 2020 and 2021. ISPAD has always been known for its friendly environment and ease of networking, so communication during this period was essential to motivate members to participate in this new model of meeting. The dedication of many people to the executive and scientific areas made it possible that virtual conferences to be so successful. ISPAD 2022 in Abu Dhabi was a return to the in-person conferences, and it was great to meet people face-to-face, with great scientific content.

We had eight ISPAD live webinars, covering topics like nutrition, physical activity, education, and communication, as well as chapters from the ISPAD Consensus Guidelines. They are all recorded and can be accessed on our website at “Resource platform”. ISPAD Webinars will continue to bring updated relevant discussions.

One of the most important novelties was the launch of the ISPAD Society app. The app is facilitating ISPAD members’ access to resources like guidelines, webinars and e-learning directly from their cellular phone or tablets. We anticipate that the ISPAD Society App (with embedded e-learning app) will become one of the most used resources, since it’s complete and easy to access. We are sure that its use will increase in the next years.

The numbers below show that interaction between ISPAD and its membership increased in the last years, through all our media channels – Website, Facebook, Twitter and the Newsletter. The number of followers and also the rate of NL sessions opening, reflects a growing engagement and interest in the Society’s activities.

ISPAD also assumed its leadership and used its channels to help children with diabetes that had to leave Ukraine to other countries in Europe. A new tab was created on the website where we put together a list with addresses of Diabetes Clinics and Associations that could receive these population and continue treatment without gaps.
The Communications Board is also responsible for celebrating special dates and calling members to vote and to participate on the board, questionnaires, and studies.

For the next period ISPAD will face new challenges regarding communications. The war in Ukraine and political polarization in many countries requires clear, fair and balanced positions from an international society as ISPAD is. The increase in the use of social media globally is a fact, and misinformation about diabetes is worrisome. There is a global need to receive information, and ISPAD has to take the leadership, so we have to keep learning how to reach our audience and to expand it, understanding that we have a great diversity of followers. We will try to always be aware of their needs and wishes, be inclusive and maintain high standards of scientific and trustable content.

Eduardo Calliari  
Roque Cardona-Hernandez

**ISPAD Website**

Between the years 2020-2021 (from July 1, 2020, to December 31, 2021), 138,573 users visited the ISPAD Website, with a return visitor rate of 18.7% and a new visitor rate of 81.3%. There have been 562,562 pageviews.

For 2022 (from January 1, 2022, to December 31, 2022), 95,137 users visited the ISPAD website, with 452,683 pageviews. Returning visitors accounted for 20% of all visitors during this time period, while new visitors accounted for 79%.

![Figure 1](#) - extracted from Google Analytics for the period from July 1, 2020, until December 31, 2021

![Figure 2](#) - extracted from Google Analytics for the period from July 1, 2022, until December 31, 2022
For the first period (from July 1, 2020, to December 31, 2021), the five countries with the most website visitors were: the United States, France, India, the United Kingdom, and Mexico, with France joining the top five list for the first time.

For 2022, the results are very similar to previous years, with India, the United States, Mexico, the United Kingdom, and Australia ranking first through fifth in terms of website visitors. India has surpassed previous periods in terms of website visitors for the first time.

<table>
<thead>
<tr>
<th>Country</th>
<th>Users</th>
<th>% Users</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>11,181</td>
<td>11.47%</td>
</tr>
<tr>
<td>United States</td>
<td>10,217</td>
<td>10.56%</td>
</tr>
<tr>
<td>Mexico</td>
<td>5,301</td>
<td>5.48%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>4,973</td>
<td>5.14%</td>
</tr>
<tr>
<td>Australia</td>
<td>3,722</td>
<td>3.85%</td>
</tr>
<tr>
<td>France</td>
<td>3,626</td>
<td>3.75%</td>
</tr>
<tr>
<td>Brazil</td>
<td>2,357</td>
<td>2.44%</td>
</tr>
<tr>
<td>Italy</td>
<td>2,195</td>
<td>2.30%</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>2,293</td>
<td>2.37%</td>
</tr>
<tr>
<td>Egypt</td>
<td>2,211</td>
<td>2.28%</td>
</tr>
</tbody>
</table>

*Figure 3 - extracted from Google Analytics for 2022 (January 1, 2022, until December 31, 2022)*

**ISPAD Society Newsletter**

For the first period (from July 1, 2020, until December 31, 2021): The open rate and click rate of the ISPAD Newsletter presents an average open rate of 30.2% and a click rate of 5.4%. (Percentage calculated on the Open Rate and Click Rate data from July 2020, July 2021 and December 2021).

For the second period in 2022 (from January 1, 2022, until December 31, 2022), the open rate and click rate of the ISPAD Newsletter presents an average open rate of 40.6% and a click rate of 8.6%. (Percentage calculated on the Open Rate and Click Rate data from January 2022, July 2022 and December 2022).

*Figure 3 - extracted from Mailchimp for the end of 2022 (December 2022)*

The five countries with the audience most interested in ISPAD News are United States, Sweden, United Kingdom, Canada, Australia.
ISPAD Facebook Account

Over the **first period from July 1, 2020, until December 31, 2021**: ISPAD continued to improve its visibility on social media. The ISPAD Facebook registered an increase of 66% followers in July 2020 comparing to previous years:

Facebook Followers

July 2020: 3386

July 2021: 4026

December 2021: 4234

For this period, the most successful Facebook post was for 11600 Reaches for the extension of the deadline to apply for the FID-ISPAD Diabetes Research Grant, posted on June 16, 2021:

*Figure 5 - extracted from Facebook*

Over the **second period from January 1, 2022, until December 31, 2022**: the increase in followers keeps steady with an increase of 10.9% from the start of 2022 until the end of 2022.

Facebook Followers

January 2022: 4250

July 2022: 4429

December 2022: 4770

For this year 2022, the most successful Facebook post was for 11600 Reaches for the celebration of the 100th Anniversary on the invention of Insulin with 11,190 reaches, posted on January 23, 2022:

*Figure 6 - extracted from Facebook*
ISPAD Twitter

In the first period, from July 1, 2020, to December 31, 2021, the ISPAD Twitter Account gained 2459 followers. Since July 1, 2020 (1839), the total number of followers has increased by 25.2%.

Over the second period, from January 1, 2022, to December 31, 2022, the number of followers increased by 18.8% from the beginning of the year (2459 followers) to the end of the year (3031 followers). The most successful Tweet in 2022 was for the celebration of the 100 years of the invention of Insulin

![ISPAD Twitter Image](image)

Figure 7 – Extracted from Twitter

Over the second period from January 1, 2022, until December 31, 2022:

This is an overview for every month in 2022:

<table>
<thead>
<tr>
<th>JAN 2022 SUMMARY</th>
<th>FEB 2022 SUMMARY</th>
<th>MAR 2022 SUMMARY</th>
<th>APR 2022 SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tweets</td>
<td>Tweet impressions</td>
<td>Tweets</td>
<td>Tweet impressions</td>
</tr>
<tr>
<td>9</td>
<td>9,631</td>
<td>9</td>
<td>7,308</td>
</tr>
<tr>
<td>Profile visits</td>
<td>Mentions</td>
<td>Profile visits</td>
<td>Mentions</td>
</tr>
<tr>
<td>1,070</td>
<td>16</td>
<td>1,130</td>
<td>21</td>
</tr>
<tr>
<td>New followers</td>
<td></td>
<td>New followers</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td>28</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAY 2022 SUMMARY</th>
<th>JUN 2022 SUMMARY</th>
<th>JUL 2022 SUMMARY</th>
<th>AUG 2022 SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tweets</td>
<td>Tweet impressions</td>
<td>Tweets</td>
<td>Tweet impressions</td>
</tr>
<tr>
<td>19</td>
<td>8,761</td>
<td>16</td>
<td>6,893</td>
</tr>
<tr>
<td>Profile visits</td>
<td>Mentions</td>
<td>Profile visits</td>
<td>Mentions</td>
</tr>
<tr>
<td>1,422</td>
<td>54</td>
<td>1,222</td>
<td>24</td>
</tr>
<tr>
<td>New followers</td>
<td></td>
<td>New followers</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td>27</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SEP 2022 SUMMARY</th>
<th>OCT 2022 SUMMARY</th>
<th>NOV 2022 SUMMARY</th>
<th>DEC 2022 SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tweets</td>
<td>Tweet impressions</td>
<td>Tweets</td>
<td>Tweet impressions</td>
</tr>
<tr>
<td>17</td>
<td>9,091</td>
<td>9</td>
<td>6,818</td>
</tr>
<tr>
<td>Profile visits</td>
<td>Mentions</td>
<td>Profile visits</td>
<td>Mentions</td>
</tr>
<tr>
<td>4,192</td>
<td>82</td>
<td>8,641</td>
<td>1,020</td>
</tr>
<tr>
<td>New followers</td>
<td></td>
<td>New followers</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td></td>
<td>143</td>
<td>65</td>
</tr>
</tbody>
</table>

ISPAD Activity Report 2020 - 2022
When comparing results from January 2022 (left figures) vs December 2022 (right figures), ISPAD had a daily average of 3.1% engagement rate. This percentage indicates the total number of times a user interacted with each tweet.

There was an average of four link clicks per day because the majority of ISPAD publications included links as a form of interaction. This increases overall engagement.

Receiving retweets is a feature that allows ISPAD’s message to be shared across a wider audience. There was an average retweet of 2 per day. This is the same number for 2020-2021.

ISPAD received 3.5 likes per day on average during this time period, and it hopes to increase this number even more over the next year by interacting with users more and promoting comments to raise engagement.

*Figures 8 & 9 - Extracted from Twitter*
VII. ISPAD Treasurer's Report

by Lars Krogvold

ISPAD has been registered as a Charity in England and Wales (Charity Number 1126927) since 2008. The Annual Accounts for the financial year are independently examined by Crowe U.K. LLP prior to their official publication on the Companies House website here.

The fiscal year being reported on below began on July 1, 2020, and ended on December 31, 2022.

Financial Review:

The current period is for the 18-month period ending 31 December 2021 (‘2021’). The prior period is for the year ended 30 June 2020 (‘2020’).

During the financial period 1 July 2020 to 31 December 2021, expenditure totaled £552,306 (2020: £606,696) and income was £819,264 (2020: £635,154).

Our financial goals are to maintain sufficient funds held in reserve to assure our continued existence under difficult financial situations (poor income years, and unusual economic times), while we continue to support funding for Science Schools, Post Graduate Courses, the Allan Drash Clinical Fellowship, Research Fellowship, Travel Grants, Pediatric Diabetes, Memberships, and special initiatives.

One of the challenges of holding our Annual Conferences in different locations around the world is the widely varying costs and benefits from them. The 2018 Conference in Hyderabad, India was a successful Conference in raising awareness across the wider region, but resulted in a negative balance, while the 45th Annual Conference in Boston, USA in 2019 resulted in a positive balance. The Annual Conferences in 2020 and 2021 were both virtual, with good attendance as mentioned and they both resulted in positive balances.

A crucial element of our charitable aims is to facilitate access to science and education, especially for young health professionals involved with diabetes. To this end we support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world). Starting from July 1, 2020, ISPAD has reduced membership and registration fees for members from Upper-middle-income countries and even more important waived membership fees for low-income countries.

The COVID-19 pandemic has definitively affected the finances of ISPAD in the previous years and will continue to do so also in the years to come (see below). We have therefore, since February 2020, worked hard to inform members and corporate members/sponsors about the new situations we are facing. To maintain our activities, ISPAD must in the coming years focus on keeping costs down, as we expect that income will likely be reduced. This is because we, like other Societies, expect a reduction in sponsored income. In addition, a reduced conference income due to reduced number of attendees as
well as higher conference implementation costs (e.g., venue rental costs, speaker travel expenses) is expected.

Reserves Policy
Our policy is to maintain reserves of sufficient funds to provide ongoing support for up to two years of Charity activity. The balance of total reserves at the year-end was £1,152,869 (2020: £885,911) of which £1,067,861 (2020: £843,665) was free reserves, this compares with £817,652 of total income in the period ended 31 December 2021, and £85,008 (2020: £42,246) was restricted. Conference income is very unpredictable and the current financial climate demands that we hold a slightly increased reserve. This is considered prudent also because corporate sponsorship has become more challenging to obtain.

Key risks and uncertainties
Like all charities, ISPAD has been facing increased risks and uncertainties due to the COVID-19 pandemic. Even though the pandemic has slowed down, we still expect changes and new challenges due to changes in i.e., willingness to travel, being paying members of Society and sponsoring Society. This leads to continuous difficulties regarding both predicted income as well as expenses.

Income:
During the pandemic, the total number of members for the first time in several years decreased. At ISPAD, we have experienced a stable increase in total membership numbers over a long period. In 2020-2021, we experienced a decrease of approximately 20%. This was mainly due to the needed repeated virtual ISPAD Conference 2021, as in 2020. Even though the virtual conferences were well attended, we missed the effects we usually observe locally. In 2019-2020 we gained a significant number of new members from North America due to ISPAD 2019 in Boston, while we had a tremendous increase in members from India and neighboring countries due to our conference in Hyderabad in 2018. The obvious reason for this local effect is a reduced conference fee for paying members. This effect was completely missing for ISPAD Virtual Conference 2020 and 2021. We are working hard to maintain our total number of members, and hope that ISPAD 2022 on site in Abu Dhabi will increase the numbers of members, both in the Region as well as worldwide.

Regarding Corporate Membership and Sponsorship, which are extremely important sources of income for ISPAD, the situation is still uncertain. So far, all key sponsors have maintained their commitments. Still, we are aware that the situation for many of our corporate collaborators is uncertain, and we should not take their support for granted in the upcoming years.

The conference income for the fiscal year 2021 was as expected, due to the high level of sponsorship income and lower expenses than with an in-person event. Regarding the on-site Conference in Abu Dhabi 2022, we expect a negative balance. This is both because of an expected reduced number of attendees and the reduced sponsorship income. Still the location is in line with the overall aim of ISPAD (as previously described), and the event is expected to raise increased knowledge and awareness of diabetes in a region of the world that up to date has never hosted an Annual ISPAD Conference. Therefore, this expected negative balance has been included in the budget and will not represent a major challenge for the overall financial situation of the Society.
Expenses:
There are still uncertainties with respect to the allocation and format of several of ISPAD core activities. This includes our science schools, both for physicians and healthcare providers, the ASPED-ISPAD-Lilly Academy, CDIC training and finally the Allan Drash fellowships. The restricted funding from different sponsors for these activities depends on the activities’ format (in-person or virtual), whereby some might be postponed later. These activities are of course very important for ISPAD as society, and we have to be flexible, dynamic and pragmatic to maintain as many as possible despite the pandemic.

In summary, there are more risks and uncertainties than usual in the current situation. Nonetheless, the financial situation is very safe within the fiscal year 2021 due to headroom given by the high level of reserves.

The Trustees undertook detailed planning and forecasting with closely monitoring of the situation since the beginning of the COVID-19 pandemic. Due to this, the Trustees believe that the Charity’s financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements. There are no material uncertainties about the ability to continue and therefore the financial statements have been prepared on a going concern basis.

Looking ahead
ISPAD has increased engagement with patient advocacy groups during this reporting year and has encouraged them to meet at our Annual Conferences and to publicize the work and mission of ISPAD. ISPAD has played a major role in communication with the community about COVID-19 safe practices and effects on the diabetes community during 2021. Our Annual Conference for 2022 will be on site in Abu Dhabi, with the opportunity to participate also virtually.

The financial environment is still challenging, primarily as a result of the COVID-19 pandemic, and new industry support rules and regulations make it more difficult for ISPAD to receive corporate membership fees or targeted grants. We are appreciative of those who have been able to continue support ISPAD.

For this reason, ISPAD offers to become a corporate member or sponsor, with different benefits. ISPAD, to enhance its relationship with companies, organizes a specific and strategic meeting (Corporate Advisory Board Meeting) annually with all companies during its Winter Meeting in February. Since 2019, this meeting has been taking place adjacent to the ATTD (Advanced Technologies and Treatments in Diabetes) in order to enable maximum industry attendance. The invoiced year for corporate membership is now the Calendar year (January to December) and hence the accounting was changed. The accounting year was transitioned from a July to June financial year to a calendar year on January 1, 2022. In order to adjust to the calendar year, the fiscal year that started on July 1, 2020, was extended by 6 months to end on December 31, 2021.

Membership payments are becoming increasingly important. The number of lapsed members might be significantly reduced by improving the payment process and the possibilities to interact with other
members. To improve payment of membership fees and to overcome some technical issues, ISPAD has requested K.I.T Group GmbH to improve the membership system and extend on the overall experience to enroll members in ISPAD activities. Now, 3 years after its implementation the system appears to be working well and membership had been steadily increasing every year until COVID-19. We hope to see an increase during 2022 because of the Annual Conference in Abu Dhabi, although this is difficult to predict with certainty.

We anticipate that ISPAD will likely face the late consequences of the COVID-19 pandemic in the upcoming fiscal years. We expect that some corporate members and sponsors may withdraw as their financial situation is uncertain. Although others may become new members, we may see a reduction in total corporate members and sponsorships. The difficulties in organizing the Annual Conference on-site may return, if so, we are unsure of how Virtual Conferences will affect both the attendance at the conference itself and the total numbers of ISPAD members. If we hopefully are to arrange on-site activities in the future as planned, expenses may likely increase as a consequence of higher international airline expenses. Therefore, maintaining reserves of sufficient funds is more important than ever for ISPAD.

We have also initiated a revised accounting system for invoicing to be performed by K.I.T. Group in conjunction with and approval by the ISPAD Treasurer. This system is designed to provide redundancy and avoid missing opportunities for ISPAD funding.

**ISPAD Corporate Members**

In a globally gloomy financial climate, our sponsors have remained loyal to the principles enshrined in our organization and continue to support the wider activities of ISPAD beyond our conference!

We are heavily dependent on our corporate sponsors in two specific ways. The Annual Conference sponsorship is managed through our conference management company, K.I.T. Group GmbH and, as such, is separate from the support specified here. This support is for ISPAD as the society and is used for all our activities, including the prestigious prizes, special travel grants, fellowships, PETC(W)A and to finance the Science Schools. Their support is gratefully acknowledged.
Corporate Members:

[Logos of various companies]

Corporate Supporters:

[Logos of various companies]

We thank our partners 2020-2021:

[Logos of various organizations]
Annual Conference Sponsors, ISPAD 2020 & 2021 (Virtual)

We would not have been able to host our conferences without the reliable support of the companies that have sponsored our Annual Conference.

For 2020, we are grateful to:

**PLATINUM**

![Medtronic](image1)

![Novo Nordisk](image2)

![Sanofi](image3)

**GOLD**

![Abbott](image4)

![Dexcom](image5)

![Lilly](image6)

![Roche](image7)

![Tandem Diabetes Care](image8)

**SILVER**

![Insulet Corporation](image9)

**GENERAL PARTNER:**

![Nordic Pharma](image10)
For 2021, we are grateful to:

**PLATINUM**

![Platinum Partners Logos]

**GOLD**

![Gold Partners Logos]

**GENERAL PARTNERS**

![General Partners Logos]
Financial Situation in 2020-2021

The analysis depicting ISPAD’s economic situation in the financial year 2020-2021 is based on the financial transactions in ISPAD's accounts for 2020-2021.

Accounts

ISPAD has 5 bank accounts. Euro and US Dollar accounts are maintained in Germany for the day to day running of the Society and are managed on ISPAD’s behalf by K.I.T. Group GmbH. There are Pound Sterling, US Dollar and Euro accounts held with Lloyds in the UK where most of the reserves are maintained. All payments, except those for day-to-day running of the Society, are approved by the Treasurer.

For this report, all figures are in £ Sterling.

Income

Total Income 2020-2021 Accounts (2019-20 in blue)

£819,264 (£635,154 2020-2020)

Expenditures

Explanatory Notes

Care must be taken in interpreting these figures as they arise from the accrual accounting system now in place which considers all transactions relating to a financial year, whether they have occurred within that time e.g., if an invoice is issued then an asset appears in the books although the money may not appear until later.

Finally, please note again that this report refers to an extended financial year that started on July 1, 2020, and ended December 31, 2021.

The financial year January 1 to December 31, 2022, will be audited by the Annual General Meeting 2023. The financial statement for that year will be linked in this report once finalized.

Lars Krogvold
ISPAD Treasurer
VIII. Society Figures and Numbers

2013 – 2022 ISPAD Membership*

*2022 figures based on membership data for 1/01/2022 to 31/12/2022

Paid members only
**ISPAD Members**

<table>
<thead>
<tr>
<th>Profession</th>
<th>Nb of members</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>640</td>
<td>61.00%</td>
</tr>
<tr>
<td>Students</td>
<td>134</td>
<td>12.77%</td>
</tr>
<tr>
<td>Nurses</td>
<td>88</td>
<td>8.39%</td>
</tr>
<tr>
<td>Other</td>
<td>39</td>
<td>3.72%</td>
</tr>
<tr>
<td>Dietitians</td>
<td>63</td>
<td>6.00%</td>
</tr>
<tr>
<td>Psychologists</td>
<td>20</td>
<td>1.90%</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>15</td>
<td>1.43%</td>
</tr>
</tbody>
</table>

* Figures based on membership at 31/12/2022
* Emeritus and Honorary members are not included (50 members = 4.8%)

![Chart showing ISPAD members distribution by profession]
ISPAD Members sorted by countries - ISPAD Members are from 123 different countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>Qty</th>
<th>Country</th>
<th>Qty</th>
<th>Country</th>
<th>Qty</th>
<th>Country</th>
<th>Qty</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>215</td>
<td>Portugal</td>
<td>6</td>
<td>Peru</td>
<td>2</td>
<td>Saint Lucia</td>
<td>1</td>
</tr>
<tr>
<td>Australia</td>
<td>86</td>
<td>Jordan</td>
<td>6</td>
<td>Malawi</td>
<td>2</td>
<td>Rwanda</td>
<td>1</td>
</tr>
<tr>
<td>India</td>
<td>82</td>
<td>France</td>
<td>5</td>
<td>Israel</td>
<td>2</td>
<td>Panama</td>
<td>1</td>
</tr>
<tr>
<td>Canada</td>
<td>53</td>
<td>Nigeria</td>
<td>5</td>
<td>Holland</td>
<td>2</td>
<td>Oman</td>
<td>1</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>46</td>
<td>Switzerland</td>
<td>5</td>
<td>Congo</td>
<td>2</td>
<td>Myanmar</td>
<td>1</td>
</tr>
<tr>
<td>Netherlands</td>
<td>39</td>
<td>Slovenia</td>
<td>5</td>
<td>Slovak Republic</td>
<td>2</td>
<td>Mauritius</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>33</td>
<td>Kenya</td>
<td>5</td>
<td>Burkina Faso</td>
<td>2</td>
<td>Malta</td>
<td>1</td>
</tr>
<tr>
<td>Italy</td>
<td>31</td>
<td>Thailand</td>
<td>5</td>
<td>Algeria</td>
<td>2</td>
<td>Lebanon</td>
<td>1</td>
</tr>
<tr>
<td>Turkey</td>
<td>20</td>
<td>Romania</td>
<td>5</td>
<td>Ukraine</td>
<td>2</td>
<td>Kosovo</td>
<td>1</td>
</tr>
<tr>
<td>Egypt</td>
<td>19</td>
<td>Qatar</td>
<td>5</td>
<td>Finland</td>
<td>1</td>
<td>Colombia</td>
<td>1</td>
</tr>
<tr>
<td>Sweden</td>
<td>17</td>
<td>South Africa</td>
<td>4</td>
<td>Bosnia and Herzegovina</td>
<td>1</td>
<td>Iran</td>
<td>1</td>
</tr>
<tr>
<td>Poland</td>
<td>16</td>
<td>Indonesia</td>
<td>4</td>
<td>Congo, The Democratic Republic of</td>
<td>1</td>
<td>Libya</td>
<td>1</td>
</tr>
<tr>
<td>Japan</td>
<td>15</td>
<td>Hong Kong</td>
<td>4</td>
<td>Iraq</td>
<td>1</td>
<td>Guyana</td>
<td>1</td>
</tr>
<tr>
<td>Denmark</td>
<td>14</td>
<td>Bangladesh</td>
<td>3</td>
<td>Singapore</td>
<td>1</td>
<td>Cyprus</td>
<td>1</td>
</tr>
<tr>
<td>New Zealand</td>
<td>14</td>
<td>Ecuador</td>
<td>3</td>
<td>Macedonia</td>
<td>1</td>
<td>Cuba</td>
<td>1</td>
</tr>
<tr>
<td>Ireland</td>
<td>13</td>
<td>Korea, South</td>
<td>3</td>
<td>Lithuania</td>
<td>1</td>
<td>Cote d'Ivoire</td>
<td>1</td>
</tr>
<tr>
<td>Belgium</td>
<td>13</td>
<td>Tanzania</td>
<td>3</td>
<td>Iceland</td>
<td>1</td>
<td>China</td>
<td>1</td>
</tr>
<tr>
<td>Greece</td>
<td>12</td>
<td>Serbia</td>
<td>3</td>
<td>Ghana</td>
<td>1</td>
<td>Bolivia</td>
<td>1</td>
</tr>
<tr>
<td>Brazil</td>
<td>12</td>
<td>Malaysia</td>
<td>3</td>
<td>Costa Rica</td>
<td>1</td>
<td>Benin</td>
<td>1</td>
</tr>
<tr>
<td>Haiti</td>
<td>12</td>
<td>Croatia</td>
<td>3</td>
<td>Honduras</td>
<td>1</td>
<td>Albania</td>
<td>1</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>11</td>
<td>England</td>
<td>3</td>
<td>Kazakhstan</td>
<td>1</td>
<td>Montenegro</td>
<td>1</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>11</td>
<td>Yemen</td>
<td>3</td>
<td>Russia</td>
<td>1</td>
<td>Niger</td>
<td>1</td>
</tr>
<tr>
<td>Sudan</td>
<td>11</td>
<td>Uganda</td>
<td>3</td>
<td>Philippines</td>
<td>1</td>
<td>Tajikistan</td>
<td>1</td>
</tr>
<tr>
<td>Nepal</td>
<td>10</td>
<td>Ethiopia</td>
<td>3</td>
<td>Liberia</td>
<td>1</td>
<td>Zimbabwe</td>
<td>1</td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>10</td>
<td>Oman</td>
<td>3</td>
<td>Jamaica</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>ISPAD Membership</td>
<td>Country</td>
<td>ISPAD Membership</td>
<td>Dominican Republic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------</td>
<td>--------------</td>
<td>------------------</td>
<td>-------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>9</td>
<td>Sri Lanka</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>9</td>
<td>Kuwait</td>
<td>2</td>
<td>Bahrain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Argentina</td>
<td>8</td>
<td>Hungary</td>
<td>2</td>
<td>Zambia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pakistan</td>
<td>8</td>
<td>Czech Republic</td>
<td>2</td>
<td>Vietnam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>7</td>
<td>Cameroon</td>
<td>2</td>
<td>Uzbekistan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>7</td>
<td>Morocco</td>
<td>2</td>
<td>Uruguay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td>6</td>
<td>Estonia</td>
<td>2</td>
<td>Syria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>6</td>
<td>Taiwan</td>
<td>2</td>
<td>Scotland</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Not specified: 6

* Data based on membership figures at 31/12/2022

* Figures based on membership at 31/12/2022
ISPAD Members sorted by age group (based on year of birth)

* Not specified: 35

* Figures based on membership at 31/12/2022

ISPAD Members sorted by Fee Type

<table>
<thead>
<tr>
<th>Fee Type</th>
<th>No. of Members</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Income</td>
<td>52</td>
<td>4,95%</td>
</tr>
<tr>
<td>Lower &amp; Upper Middle Income</td>
<td>231</td>
<td>22,02%</td>
</tr>
<tr>
<td>Standard</td>
<td>716</td>
<td>68,25%</td>
</tr>
<tr>
<td>Emeritus and Honorary</td>
<td>50</td>
<td>4,76%</td>
</tr>
</tbody>
</table>

No. Members by Fee Type

- Low Income
- Standard
- Lower & Upper Middle Income
- Emeritus and Honorary
International Society for Paediatric and Adolescent Diabetes (ISPAD)
c/o K.I.T. Group GmbH
Kurfürstendamm 71
10709 Berlin
Germany
Phone: +49 30 24603210
Fax: +49 30 24603200
E-Mail: secretariat@ispad.org
www.ispad.org